The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
本发明提供了新型的取代异噁唑化合物、制备这些化合物的药物组合物、治疗用途和制备过程。
Farnesoid X receptor agonists
申请人:GlaxoSmithKline LLC
公开号:US08158665B2
公开(公告)日:2012-04-17
The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
本发明提供了新型的取代异噁唑化合物、药物组合物、治疗用途及其制备方法。
Farnesoid X Receptor Agonists
申请人:Caldwell Richard
公开号:US20100160398A1
公开(公告)日:2010-06-24
The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
本发明提供了新型取代异噁唑化合物、制药组合物、治疗用途和制备方法。
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064
作者:Jonathan Y. Bass、Richard D. Caldwell、Justin A. Caravella、Lihong Chen、Katrina L. Creech、David N. Deaton、Kevin P. Madauss、Harry B. Marr、Robert B. McFadyen、Aaron B. Miller、Derek J. Parks、Dan Todd、Shawn P. Williams、G. Bruce Wisely
DOI:10.1016/j.bmcl.2009.04.047
日期:2009.6
Starting from the known FXR agonist GW 4064 1a, a series of alternately 3,5-substituted isoxazoles was prepared. Several of these analogs were potent full FXR agonists. A subset of this series, with a tether between the isoxazole ring and the 3-position aryl substituent, were equipotent FXR agonists to GW 4064 1a, with the 2,6-dimethyl phenol analog 1t having greater FRET FXR potency than GW 4064 1a. (C) 2009 Elsevier Ltd. All rights reserved.